)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Shattuck Labs (STTK) investor relations material
Shattuck Labs Evercore ISI 8th Annual HealthCONx Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Evercore ISI 8th Annual HealthCONx Conference summary4 Dec, 2025
Scientific rationale and differentiation
Targeting the TL1A receptor (DR3) offers potential advantages over ligand-blocking, including reduced immunogenicity and improved efficacy due to stable receptor expression on lymphocytes.
Ligand-blocking antibodies form immune complexes that drive high rates of antidrug antibodies (ADA), while receptor-blocking avoids this liability.
The receptor is not shed, eliminating immune complex formation and associated toxicity seen in ligand-blocking approaches.
Blocking the receptor ensures all TL1A-mediated inflammation and fibrosis are addressed, as TL1A only signals through DR3.
Persistent receptor blockade may provide more consistent efficacy compared to chasing pulsatile ligand expression.
Preclinical and clinical progress
Preclinical studies in non-human primates showed no evidence of receptor agonism or toxicity at any dose.
Phase 1 study in healthy volunteers is about halfway complete, with early indicators supporting a differentiated immunogenicity profile.
Receptor occupancy and lack of ADA in phase 1 are expected to provide confidence for efficacy in future patient studies.
Chronic toxicology studies are ongoing for both the lead and half-life extended antibody variants, with clinical readiness expected post-study.
Plans include rapid transition to phase 2 studies in non-IBD indications, leveraging recent financing.
Competitive landscape and future plans
Multiple TL1A programs are advancing, with up to four new indications expected to report data next year.
The company is not waiting for backup molecules and is prioritizing non-IBD phase 2 studies.
Half-life extension and bispecific antibody programs are in development, with the potential for quick clinical integration.
Combination strategies, including DR3 bispecifics with IL-23, are under consideration for future trials.
A large phase 2 platform trial with multiple indications and biosimilar combinations is possible within the next few quarters.
Confirm DR3 target's immunogenicity profile
Detail persistent receptor blockade efficacy thesis
Outline DR3 bispecific and half-life extension plans
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Shattuck Labs earnings date
Q4 202527 Feb, 2026
Next Shattuck Labs earnings date
Q4 202527 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Shattuck Labs Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer and autoimmune diseases. The company leverages its proprietary Agonist Redirected Checkpoint (ARC) platform to create biologic therapies that enhance the body's immune response. Shattuck Labs' technology is designed to modulate immune pathways, potentially improving outcomes for patients with challenging conditions. The company is involved in research and development efforts, advancing its immunotherapy candidates through clinical trials. The company is headquartered in Durham, North Carolina, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage